UNSPSC 51292207: Itopride hydrochloride

This classification denotes an antidepressant agent with the molecular formula C20H26N2O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2H9NV66W0I, chemically known as n-((4-(2-(dimethylamino)ethoxy)phenyl)methyl)-3,4-dimethoxybenzamide monohydrochloride but more generally known as itopride hydrochloride, which bears US NIH Compound Identifier 129791. European Medicines Agency schedules Itopride hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16440MIG.

UNSPSC 51292207 Itopride hydrochloride is a Commodity code nominally identifying a single pharmaceutical product, but the recent state and local opportunities tagged under it reflect broader pharmaceutical procurement activity—naloxone distribution, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. State and local issuing bodies soliciting under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. The scope of work encompasses acquisition of specific branded or generic pharmaceuticals for public health initiatives, community health delivery, state employee health plans, and distribution through authorized pharmaceutical wholesalers. Issuing bodies range from single-county procurement (Seminole County, Florida) to statewide programs (Texas Health and Human Services Commission) and multistate cooperative vehicles (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and subordinate participating jurisdictions).

Recent activity spans Florida, Texas, and the upper Midwest. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities for a Therapeutic Pharmacy Initiative. The Minnesota Department of Administration, administering the MMCAP cooperative, posted RFP S1070000015802 on January 20, 2026, seeking generic multi-source pharmaceuticals and OTC products from manufacturers for supply through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.) with proposals due March 26, 2026. All three solicitations emphasize compliance with FDA requirements, cGMP certification where applicable, and drug supply chain security; the MMCAP RFP notes a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation.